Monoclonal Antibody to MAGE-1 (Target for Cancer Immunotherapy) (Clone : MZ2E/838)

Recognizes a protein of 42-46kDa, identified as MAGE-1. This MAb does not cross-react with other members of MAGE-family. Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL) . The MAGE family of genes codes an important group of antigens. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs) . Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy.

Product Specifications

Product Name Alternative

MAGEA1||MAGE1||MAGE1A

Gene Name

MAGEA1

Gene ID

4100

UniProt

P43355

Host

Mouse

Reactivity

Human

Immunogen

Recombinant human MAGEA1 protein

Target Antigen

MAGE-1 (Target for Cancer Immunotherapy)

Clonality

Monoclonal

Clone

MZ2E/838

Applications

FACS, IF, IHC

Purification

Affinity Chromatography

Format

Purified

Components

100 μg in 500 μl PBS containing 0.05% BSA and 0.05% sodium azide. Sodium azide is highly toxic.

Storage Conditions

Store the antibody at 4°C; stable for 6 months. For long-term storage; store at -20°C. Avoid repeated freeze and thaw cycles.

Applications Notes

Flow Cytometry (1-2ug/million cells) ; Immunofluorescence (1-2ug/ml) ; Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT) (Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95&degC followed by cooling at RT for 20 minutes)